A Diverse Region, a Unified Focus on Growth
The Asia-Pacific (APAC) region is a key pillar in Strides Pharma’s global operations, supported by a combination of Strides-owned subsidiaries and strategic partnerships. With commercial presence across Australia, New Zealand, Singapore, and a distributor-led model in markets such as Vietnam, Malaysia, Thailand, the Philippines, and China, we operate flexibly through customer solutions, partnership solutions, and joint venture models tailored to each market’s needs.
At the heart of our APAC operations lies a robust manufacturing base in India, which holds approvals from major global regulators and supplies quality medicines to over 100 countries. We offer a focused portfolio of prescription generics across key therapeutic areas such as anti-infectives, CNS, cardiovascular, gastroenterology, and pain management, with some markets also featuring specialty products. Navigating a complex regulatory landscape, we ensure compliance with standards like TGA in Australia and the ASEAN Common Technical Dossier (ACTD) to maintain speed-to-market and quality assurance.
With rising demand for affordable healthcare and broader access to generics, APAC continues to be a priority region. Our approach centers on regulatory agility, commercial adaptability, and deepening partnerships positioning Strides to play a meaningful role in advancing healthcare across the region.
India
Manufacturing Excellence, Delivered Globally
India serves as the global headquarters of Strides Pharma Science Limited, anchoring our leadership, innovation, and manufacturing excellence. Based in Bengaluru, our corporate office drives strategic direction across markets, while our operations in India form the backbone of our global supply chain delivering products to over 100 countries.
Strides’ R&D centre in Bengaluru is a key innovation hub focused on the development of complex generics, novel drug delivery systems, and value-added formulations. With strong capabilities in product development, regulatory filing, and technology transfer, the centre plays a critical role in supporting our front-end operations across regulated and emerging markets.
Strides operates four world-class manufacturing facilities in India located in Bengaluru (KRSG and SEML), Puducherry, and Chennai serving as the backbone of our global supply network. These facilities together span over 1.8 million sq. ft., with a dedicated manufacturing area of nearly 890,000 sq. ft., enabling the production of over 12 billion dosage units annually. Our capabilities cover tablets, hard gelatin capsules, sachets, liquids, suspensions, and powders. Spread across strategic locations, our facilities are accredited by global regulatory agencies such as the USFDA, TGA, WHO, MHRA, and ANVISA, enabling seamless supply to both regulated and emerging markets. Our infrastructure is designed for scale, flexibility, and sustained compliance powering our commitment to make reliable medicines accessible globally.
Australia
Trusted Partner in a Regulated Market
Strides Pharma’s presence in Australia reflects our commitment to serving highly regulated markets with reliable, accessible, and patient-focused generic medicines. Operating through a wholly owned subsidiary, Strides Australia offers a diverse portfolio of prescription pharmaceuticals that align with local therapeutic needs and regulatory standards.
Our Australian business is supported by filings with the Therapeutic Goods Administration (TGA) and benefits from Strides’ global manufacturing network, including TGA-approved facilities in India. This ensures efficient supply and consistent product quality across a broad range of therapeutic categories. Strides Australia engages in both private and government healthcare channels, helping expand access to essential treatments while maintaining compliance with national healthcare frameworks.
With a strong local presence and a globally integrated model, Strides continues to grow its footprint in Australia by focusing on portfolio expansion, supply chain reliability, and long-term value creation for healthcare providers, partners, and patients.
New Zealand
Committed to Access and Affordability
Strides Pharma operates in New Zealand through a wholly owned subsidiary, supporting the national healthcare system with a growing portfolio of affordable and trusted generic medicines. Our presence in the market is anchored by regulatory compliance with Medsafe, New Zealand’s medicines and medical devices safety authority, and supported by Strides’ global supply and development capabilities.
Strides New Zealand focuses on therapeutic areas that align with local healthcare priorities, working closely with procurement bodies, pharmacies, and healthcare providers. Products are sourced from internationally accredited manufacturing sites, including TGA- and USFDA-approved facilities in India, ensuring dependable quality and timely availability across the country.
As New Zealand continues to prioritize access, sustainability, and cost-effectiveness in its healthcare delivery, Strides remains a committed partner offering consistent value through reliable supply, expanding treatment options, and a strong alignment with national health goals.
